An open trial of adjunctive sertraline in the treatment of chronic schizophrenia

Acta Psychiatrica Scandinavica

Volumn 94, Issue 3, 1996, Pages 194-197

  Thakore, J H ^a   Berti, C ^b   Dinan, T G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Negative symptoms; Schizophrenia; Sertraline

Indexed keywords

NEUROLEPTIC AGENT; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; HUMAN; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0029806888     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb09848.x     Document Type: Article

References (30)

1. JACKMAN H, LUCHINS D, MELTZER HY. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biol Psychiatry 1983: 18: 887-902.
2. DELISI L, NECKERS L, WEINBERGER D, WYATT RJ. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 1981: 38: 647-650.
3. FREEDMAN D, BELENDIUK K, CRAYTON J. Blood tryptophan metabolism in chronic schizophrenics. Arch Gen Psychiatry 1980: 38: 655-659.
4. LERER B, RAN A, BLACKER M et al. Neuroendocrine responses in chronic schizophrenia: evidence for serotonergic dysfunction. Schizophr Res 1988: 1: 405-410.
5. IRWIN MR, MARDER SR, FUENTENEBRO F et al. L-5-hydroxytrytophan attenuates positive psychotic symptoms in treatment refractory schizophrenia. Psychiatr Res 1987: 22: 283-289.
6. STAHL SM, UHR SB, BERER PA. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic patients with remitted post-psychotic depression. Am J Psychiatry 1985: 20: 1098-1102.
7. MARSHALL BD JR, GLYNN SM, MIDHA KK et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989: 9: 110-115.
8. ALPHS LD, LAFFERMAN JA, ROS L. Fenfluramine treatment of negative symptoms in older schizophrenics. Psychopharmacol Bull 1989: 25: 149-153.
9. RENTJYENS A, GELDERS YG, HOPPENBROWERS ML, VADDENBUSCHE G. Thymosthenic effects of ritanserin, a centrally acting serotonergic receptor blocker. Drug Dev Res 1986: 8: 205-211.
10. DUINKERKE SJ, BOTTER PA, JANSEN AAI et al. Ritanserin, a 5HT2/1C antagonist, and negative symptoms in schizophrenia: an add-on double-blind, controlled study. Br J Psychiatry 1993: 163: 451-455.
11. KANE J, HONIGFIELD G, SINGER J, MELTZER HY and the Clozaril Collaboration Study Group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988: 45: 789-796.
12. JOHNSTONE EC, CROW TJ, FRITH CD et al. Mechanism of the antipsychotic effect in the acute treatment of schizophrenia. Lancet 1978: ii: 848-851.
13. ANGRISI B, ROTROSEN J, GERSHON S. Differential effects of neuroleptics on negative symptoms in schizophrenia. Psychopharmacology 1980: 72: 17-19.
14. SIRIS SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993: 163 (Suppl. 22) 66-78.
15. BRENNER R, SHOPSIN B. The use of monoamine oxidase inhibitors in schizophrenia. Biol Psychiatry 1980: 15: 633-647.
16. SIRIS SG, BERMANZOHN PC, GONZALEZ A et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 1991: 27: 331-335.
17. SILVER H, NASSAR A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind placebo-controlled study. Biol Psychiatry 1992: 31: 698-704.
18. GOFF DC, BROTMAN AW, WAITES M et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990: 147: 492-494.
19. DOOGAN DP, GAILLARD V. Sertraline: a new antidepressant. J Clin Psychiatry 1988: 49 (Suppl. 1): 46-51.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd edn. Washington, DC: American Psychiatric Association Press, 1987.
21. ANDREASEN NC. Scale for the assessment of negative symptoms (SANS). Iowa City: The University of Iowa, 1983.
22. OVERALL JE, GRAHAM DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962: 10: 799-812.
23. GUY W. Abnormal Involuntary Movement Scale. In: ECDEU assessment manual. Rockville: National Institute of Mental Health, 1976: 534-537.
24. BARNES TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989: 154: 672-676.
25. SIMPSON GM, ANGUS JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970: 212 (Suppl. 1): 11-19.
26. Statistical Graphics Corporation. Statgraphics Version 2.7. New York: Statistical Graphics Corporation, 1987.
27. WALDEMEIER PC, DELINI-STIJLA AA. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979: 55: 363-373.
28. HERVE D, SIMON H, BLANC G et al. Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesion of the median raphe in the rat. Brain Res 1981: 216: 422-428.9 SALLER CF, CZUPRYNA MJ, SALAMA AI. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990: 253: 1162-1170.
29. HERVE D, SIMON H, BLANC G et al. Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesion of the median raphe in the rat. Brain Res 1981: 216: 422-428.9 SALLER CF, CZUPRYNA MJ, SALAMA AI. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990: 253: 1162-1170.
30. COSTALL B, NAYLOR RJ, TYERS MB. Recent advances in the neuropharmacology of 5-HT3 agonists and antagonists. Rev Neurosci 1988: 2: 41-65.